Domotek
Develops the DomoBIO multi-technology bioprinter integrating electrospinning and multiple extrusion methods to enable cost-effective, multi-material tissue engineering and regenerative medicine research.
- CEO / Founder
- Francisco Palacios
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- €2.5M
- Latest Round
- Grant
- Key Investors
- Equifund, SIF IIU UIC, private investors, NEOTEC Program (CDTI)
Technology & Products
Key Products
DomoBIO; DomoBIO4A
Technological Advantage
Technology moat: Proprietary hybrid integration of electrospinning with syringe, filament, and pellet extruders in a single modular system, enabling multi-material scaffold production at a lower price point than incumbents. Claimed: Democratizes biofabrication through a cost-effective, multi-tool hybrid system. Verified: System capability for extrusion bioprinting of alginate-based bioinks confirmed in 2024 peer-reviewed research.
Differentiation
Value Proposition
Reduces R&D capital expenditure by providing a single hybrid platform (electrospinning + multiple extrusion types) that replaces multiple specialized machines, lowering the barrier to entry for complex biofabrication.
How They Differentiate
Differentiates from Cellink and Organovo by offering integrated electrospinning and pellet extrusion capabilities in a single modular unit, providing higher material versatility for research at a lower entry cost.
Market & Competition
Target Customers
Medical researchers in regenerative medicine, tissue engineering, drug manufacturing, and biosensing.
Industry Verticals
Medical; Regenerative Medicine; Tissue Engineering; Drug Manufacturing; Material Research; Biosensing
Competitors
Organovo; Cellink; Revotek; Axolotl Biosciences; FABRX
Growth & Milestones
Growth Metrics
Developed the first Spanish multi-technology bioprinter; transitioned from a 3D printing service provider to a specialized bioprinting hardware manufacturer.
Major Milestones
DomoBIO4A bioprinter utilized and cited in 2024 peer-reviewed research for extrusion bioprinting; Active presence in 2025 biotech and biomechanics event contexts
Notable Customers
Biodonostia Health Research Institute, Tecnalia Research & Innovation, University of the Basque Country (UPV/EHU).